Pfizer boss says third Covid-19 jab 'likely needed' within 12 months

Brenda Watkins
April 16, 2021

During a recently aired interview, Bourla said that patients will "likely" need an additional dose of the vaccine within 12 months of becoming fully vaccinated with the two required doses.

A study published earlier this month stated that the Pfizer vaccine is overall 91 per cent effective and 95 per cent effective against severe cases of infection up to six months after the second dose.

The head of Pfizer said Thursday the company's Covid vaccine, among the priciest on the market, is no more expensive than the cost of a meal and will not be sold to poor countries for a profit.

This came according to the statement of Pfizer CEO, Albert Bourla, said while speaking on a CVS-hosted panel on the vaccination effort that people will likely need a booster dose of a COVID-19 vaccine within 12 months of getting fully vaccinated.

"We need to see what would be the sequence, and for how often we need to do that, that remains to be seen", Bourla told CNBC in an interview recorded on April 1.

Based on the data, the CEO said there was a need for re-vaccination between six and 12 months and also an annual re-vaccination.

He explained that there are vaccines like polio, that one dose is enough and there are vaccines like flu that you need every year.

Joe Biden to 'withdrawal all U.S. troops from Afghanistan by September 11'
Officially, there are 2,500 U.S. troops in Afghanistan, although the number fluctuates and is now around 3,500. The US national intelligence report states that the Taliban "is confident it can achieve military victory".

However, more data is needed to determine if protection lasts beyond six months.

The United States is preparing for the possibility that a booster shot will be needed between nine to 12 months after people are initially vaccinated against Covid-19, a White House official said on Thursday.

A Northewell Health nurse inoculates a sheet metal worker with the first dose of the Pfizer vaccine.

Though, the vaccines have not yet been tested in on pregnant women, Dr. Al Khenyab has said that evidence from non-clinical studies of the Pfizer and BioNTech vaccine has been reviewed by the World Health Organization and the regulatory bodies in the USA, Canada and Europe and has raised no concerns about safety in pregnancy. It seems strong but there is some waning of that and no doubt the variants challenge. they make these vaccines work harder.

The booster shot is aimed at protecting against future variants, which may be better at evading antibodies from vaccine than earlier strains of the virus.

About 144 volunteers will be given the third dose, mostly those who participated in the vaccine's early-stage United States testing previous year.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER